Immune globulin subcutaneous (human)-hipp - Biologic Drug Details

Summary for immune globulin subcutaneous (human)-hipp

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	2

Pharmacology for immune globulin subcutaneous (human)-hipp

Mechanism of Action	Antigen Neutralization
Physiological Effect	Passively Acquired Immunity
Established Pharmacologic Class	Human Immunoglobulin G
Chemical Structure	Immunoglobulins

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. General brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for immune globulin subcutaneous (human)-hipp Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for immune globulin subcutaneous (human)-hipp Derived from Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for immune globulin subcutaneous (human)-hipp Derived from Patent Text Search

No patents found based on company disclosures

Immune globulin subcutaneous (human)-hipp Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory of Subcutaneous Immunoglobulin (SCIG)

Introduction to Subcutaneous Immunoglobulin (SCIG)

Subcutaneous Immunoglobulin (SCIG) is a biologic drug used primarily to treat primary and secondary immunodeficiency diseases. It has gained significant traction in recent years due to its efficacy, patient preference, and cost savings compared to traditional intravenous immunoglobulin (IVIG) treatments.

Market Size and Growth Projections

The SCIG market is experiencing robust growth, driven by several key factors. As of 2024, the market size is estimated to be around USD 11.70 billion and is projected to reach USD 19.70 billion by 2029, growing at a compound annual growth rate (CAGR) of 11% during the forecast period[1][4].

Impact of the COVID-19 Pandemic

The COVID-19 pandemic had a notable impact on the SCIG market. Clinical trials were delayed, and patient enrollment rates decreased significantly. For instance, data from ClinicalTrials.gov indicated that over 200 interventional oncology studies were suspended due to the pandemic. However, the market has since recovered, and research activities have resumed, contributing to the anticipated strong growth[1].

Key Drivers of Market Growth

Increasing Prevalence of Immunodeficiency Diseases

The rising burden of immunodeficiency diseases, such as HIV and common variable immunodeficiency (CVID), is a significant driver of market growth. For example, India reported around 2.4 million HIV cases in 2022, and CVID affects up to 1 in 25,000 people worldwide, contributing to the increasing demand for SCIG treatments[1].

Growing Geriatric Population

The increasing geriatric population is another factor driving the market. Older adults are more prone to immunodeficiency diseases, which in turn increases the demand for SCIG therapies[1].

Patient Preference and Cost Savings

Patients prefer SCIG over IVIG due to its convenience and reduced side effects. Studies have shown that shifting from IVIG to SCIG can result in significant cost savings. For instance, a German cost-minimization analysis found that switching patients from hospital-based IVIG to home-based SCIG resulted in total savings of $7,592 per patient over three years[2].

Expanding Applications

SCIG is increasingly being used for various neurological and dermatological conditions, expanding its market scope. Innovations in drug delivery systems, formulations, and antibody therapies are also driving market growth[4].

Regional Market Dynamics

North America

North America is expected to dominate the SCIG market during the forecast period. This dominance is attributed to the presence of key players, high prevalence of immunodeficiency diseases, an aging population, and a well-established healthcare infrastructure. The region also sees a high burden of cancer, which further contributes to the market growth[1].

Economic Burden and Cost Considerations

Treatment Costs

The cost of SCIG is significant but offers long-term cost savings. Annual treatment costs for patients with primary immunodeficiencies can decline substantially after diagnosis and initiation of SCIG treatment. For example, a report by the Jeffrey Modell Foundation found that annual treatment costs decreased from $111,053 per patient before diagnosis to $25,271 after diagnosis, even before accounting for the cost of Ig treatment[2].

Site of Care and Delivery Method

The cost of SCIG is directly related to the type of delivery method and the site of care. Shifting from hospital-based IVIG to home-based SCIG has been shown to reduce medical and non-medical costs, including travel expenses and parental time[2].

Market Segmentation

By Product

The SCIG market is segmented by product, with IgG being the highest revenue-grossing segment in 2023 due to growing acceptance and regulatory approvals. IgA is predicted to grow at the fastest CAGR during the forecast period due to increasing product launches and research endeavors[5].

By Application

Secondary immunodeficiency diseases, such as AIDS and immune system-related cancers, were the highest revenue-grossing segment in 2023. However, primary immunodeficiency diseases are expected to grow at the fastest CAGR due to the rising use of interventions to boost the immune system and the development of innovative treatment alternatives[5].

Innovations and Trends

Advancements in Drug Delivery Systems

Innovations in drug delivery systems are a major trend in the SCIG market. These advancements enhance the efficacy and convenience of SCIG treatments, making them more appealing to patients and healthcare providers[4].

Increasing Demand for Home Infusion Therapies

There is a growing demand for home infusion therapies, which aligns with patient preferences for convenience and reduced healthcare costs. Studies have consistently shown that home-based SCIG is preferred by patients and results in significant cost savings[2].

Developments in Antibody Therapy

Developments in antibody therapy are expanding the applications of SCIG. New formulations and innovations in antibody therapies are expected to drive market growth in the coming years[4].

Challenges and Opportunities

Undiagnosed and Underdiagnosed Cases

Primary immunodeficiencies often remain undiagnosed, underdiagnosed, or misdiagnosed, which increases the risk of mortality for patients and results in higher costs for payers. Early diagnosis and appropriate treatment can significantly reduce these costs and improve patient outcomes[2].

Regulatory Approvals and Research

The market is expected to benefit from increasing regulatory approvals of novel products and a surge in research and development endeavors. These factors will continue to drive innovation and growth in the SCIG market[5].

Key Takeaways

• The SCIG market is projected to grow significantly, reaching USD 19.70 billion by 2029.
• The COVID-19 pandemic had a temporary impact on the market, but it has since recovered.
• Increasing prevalence of immunodeficiency diseases, growing geriatric population, and patient preference for SCIG are key drivers of market growth.
• North America is expected to dominate the market due to its established healthcare infrastructure and high prevalence of immunodeficiency diseases.
• Innovations in drug delivery systems, increasing demand for home infusion therapies, and developments in antibody therapy are major trends driving the market.

FAQs

Q: What is the projected market size of the SCIG market by 2029? A: The SCIG market is expected to reach USD 19.70 billion by 2029[1].

Q: How did the COVID-19 pandemic affect the SCIG market? A: The pandemic caused delays in clinical trials and reduced patient enrollment rates, but the market has since recovered and is expected to witness strong growth[1].

Q: What are the main drivers of the SCIG market growth? A: The main drivers include the increasing prevalence of immunodeficiency diseases, growing geriatric population, patient preference for SCIG, and cost savings associated with home-based treatments[1][2].

Q: Which region is expected to dominate the SCIG market during the forecast period? A: North America is expected to dominate the market due to the presence of key players, high prevalence of immunodeficiency diseases, and a well-established healthcare infrastructure[1].

Q: What are the cost implications of switching from IVIG to SCIG? A: Studies have shown that switching from IVIG to SCIG can result in significant cost savings, including reduced medical and non-medical costs such as travel expenses and parental time[2].

Sources

1. Mordor Intelligence: Subcutaneous Immunoglobulin Market Size & Share Analysis.
2. AJMC: Managing Cost of Care and Healthcare Utilization in Patients Using Immunoglobulin Agents.
3. PubMed: Immune globulin subcutaneous, human - klhw 20% for primary immunodeficiency diseases.
4. The Business Research Company: Subcutaneous Immunoglobulin (SCIG) Global Market Report 2024.
5. PR Newswire: Global Subcutaneous Immunoglobulin Market Analysis & Forecast 2024-2034 by Product, Application, End User, and Region.